NVIDIA, IDXX and Microsoft shine on ESG metrics, fueling investor interest with strong returns and ambitious 2030 goals.

Here is how Idexx Laboratories (IDXX) and Artivion (AORT) have performed compared to their sector so far this year.

VCYT, IDXX and ISRG ride on genAI-powered growth as medical instruments evolve, even with weak industry returns and cost pressures.

Pet spending stayed resilient in 2025 despite inflation. See which pet care stocks Wall Street is watching heading into 2026.

IDEXX Laboratories (NASDAQ: IDXX - Get Free Report) and Atossa Genetics (NASDAQ: ATOS - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership. Profitability This table compares IDEXX Laboratories and Atossa

Chapin Davis Inc. purchased a new position in IDEXX Laboratories, Inc. (NASDAQ: IDXX) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 7,934 shares of the company's stock, valued at approximately $5,069,000. IDEXX Laboratories makes up about 1.2% of Chapin Davis Inc.'s investment

Assenagon Asset Management S.A. reduced its stake in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 10.9% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 55,868 shares of the company's stock after selling 6,863 shares during the period. Assenagon Asset Management S.A. owned

Corient Private Wealth LLC lessened its stake in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 2.5% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 117,474 shares of the company's stock after selling 3,030 shares during the quarter. Corient Private Wealth LLC

ISRG, PODD, BSX and IDXX lead medtech innovation with AI, robotics and diagnostics for growth in 2026.

Bamco Inc. NY lessened its position in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 1.3% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,032,620 shares of the company's stock after selling 27,157 shares during the quarter. IDEXX Laboratories comprises about 3.0% of